| Dr Katherine Lynn Snyder, PHD | |
|
204 Clement St, San Francisco, CA 94118-2408 | |
| (415) 933-6926 | |
| Not Available |
| Full Name | Dr Katherine Lynn Snyder |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 204 Clement St, San Francisco, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043438914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY7824 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katherine Lynn Snyder, PHD 204 Clement St, San Francisco, CA 94118-2408 Ph: (415) 933-6926 | Dr Katherine Lynn Snyder, PHD 204 Clement St, San Francisco, CA 94118-2408 Ph: (415) 933-6926 |
News Archive
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).
As the question of how best to deal with privatization of alcohol sales and drinking and driving continue to be debated in Ontario, the Ontario Public Health Association and the Centre for Addiction and Mental Health (CAMH) are pleased to present the seventh annual forum, aptly entitled Alcohol: No Ordinary Commodity.
A deep look into a nationwide mass vaccination setting in Israel revealed that the BNT162b2 (Pfizer–BioNTech) vaccine is not linked with an elevated risk of a majority of the adverse events under study, with the exception of myocarditis. However, even that potentially severe adverse event is much more pervasive following the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), found a new study published in the New England Journal of Medicine (NEJM).
Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.
› Verified 8 days ago
B L. Elliott, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 747 Front St, San Francisco, CA 94111 Phone: 707-508-6341 | |
Dr. David Tim Lewis, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 703 Market St Ste 1208, San Francisco, CA 94103 Phone: 415-350-9611 | |
Candy Ho Katoa, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 401 Parnassus Ave, Lp 488, San Francisco, CA 94143 Phone: 415-476-7133 | |
Stephanie Lauren Post, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1630 Lombard St, San Francisco, CA 94123 Phone: 703-901-6833 | |
Anett Atman, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 3600 California St, San Francisco, CA 94118 Phone: 415-820-9612 | |
Dr. Andrea Samuels, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1947 Divisadero St Ste 1d, San Francisco, CA 94115 Phone: 510-847-4858 | |
Timothy Kim, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1610 Scott St, San Francisco, CA 94115 Phone: 510-365-5066 |